Richter transformation describes the development of an aggressive lymphoma in patients with chronic lymphocytic leukaemia, most commonly into a diffuse large B-cell lymphoma (DLBCL).1 In contrast to the substantial advances in treatments for chronic lymphocytic leukaemia, which have contributed to improved survival outcomes in these patients, the prognosis for patients with Richter transformation remains dismal. Response to chemotherapeutic approaches that mirror de-novo DLBCL therapy is poor, and 1-year overall survival rates are lower than 50%.